Published in Hosp Prog on February 01, 1981
Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem (1983) 9.32
Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A (1983) 3.52
Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry (1983) 3.49
Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res (1982) 2.70
Synthetic peptides corresponding to keratin subunits elicit highly specific antibodies. J Biol Chem (1984) 1.96
Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology (1997) 1.87
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry (2002) 1.73
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology (1995) 1.71
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys (2002) 1.61
Hypothalamic regulatory hormones. Annu Rev Biochem (1978) 1.60
Klüver-Bucy syndrome after bilateral selective damage of amygdala and its cortical connections. J Neuropsychiatry Clin Neurosci (1998) 1.59
Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities. Arch Biochem Biophys (1989) 1.41
Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene (1994) 1.30
Purification and characterization of human recombinant interleukin-1 beta. J Biol Chem (1987) 1.16
Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol (1998) 1.16
Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer (2004) 1.15
Postoperative mutism in neurosurgery. Report of two cases. J Neurosurg (1994) 1.13
Relationship between quality of life and mood in long-term survivors of breast cancer treated with mastectomy. Support Care Cancer (1997) 1.07
Highly active position eight analogues of somatostatin and separation of peptide diastereomers by partition chromatography. Biochemistry (1978) 1.07
Synthesis and biological actions of prosomatostatin. Proc Natl Acad Sci U S A (1980) 1.07
A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol (2011) 1.05
Orientation of peptide fragments from Sos proteins bound to the N-terminal SH3 domain of Grb2 determined by NMR spectroscopy. Biochemistry (1994) 1.02
Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest (1995) 0.98
Solution structure of the Grb2 N-terminal SH3 domain complexed with a ten-residue peptide derived from SOS: direct refinement against NOEs, J-couplings and 1H and 13C chemical shifts. J Mol Biol (1997) 0.98
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res (1997) 0.98
Psychosocial functioning and quality of life in patients with primary brain tumors. J Neurosurg (1996) 0.94
Ventricular enlargement after closed head injury. Arch Neurol (1981) 0.94
Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol (1996) 0.93
Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys (1995) 0.92
Developing a care giver quality-of-life instrument. Preliminary steps. Cancer Pract (1997) 0.92
Potent, highly selective inhibition of growth hormone secretion by position 4 somatostatin analogs. Endocrinology (1981) 0.90
Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer (2001) 0.90
Secretion of N-glycosylated interleukin-1 beta in Saccharomyces cerevisiae using a leader peptide from Candida albicans. Effect of N-linked glycosylation on biological activity. J Biol Chem (1991) 0.90
A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support Care Cancer (1996) 0.89
Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci (1995) 0.89
The hippocampus: normal anatomy and pathology. AJR Am J Roentgenol (1998) 0.88
NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res (2000) 0.88
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs (1998) 0.86
Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J Med Chem (1996) 0.86
Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics (2000) 0.86
Structure-activity studies with somatostatin: the role of tryptophan in position 8. Regul Pept (1980) 0.85
Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol (2011) 0.85
Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors. Cancer (1997) 0.84
Mutism after closed head injury. Arch Neurol (1983) 0.84
Transforming growth factors from a human tumor cell: characterization of transforming growth factor beta and identification of high molecular weight transforming growth factor alpha. Biochemistry (1985) 0.83
The multisubunit IkappaB kinase complex shows random sequential kinetics and is activated by the C-terminal domain of IkappaB alpha. J Biol Chem (1998) 0.82
Linguistic recovery after closed head injury. Brain Lang (1981) 0.82
Early versus late lateral ventricular enlargement following closed head injury. J Neurol Neurosurg Psychiatry (1983) 0.82
Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay. Pharmacol Biochem Behav (1978) 0.81
[Phe4]somatostatin: a potent, selective inhibitor of growth hormone release. Proc Natl Acad Sci U S A (1980) 0.81
Selective inhibition of glucagon and insulin secretion by somatostatin analogs. Proc Soc Exp Biol Med (1979) 0.80
Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol (2000) 0.80
Gastrointestinal secretory, motor, circulatory, and metabolic effects of prosomatostatin. Proc Natl Acad Sci U S A (1981) 0.79
Somatostatin, basic and clinical studies. A review. Mater Med Pol (1982) 0.79
Medical problems encountered during rehabilitation of patients with head injury. Arch Phys Med Rehabil (1985) 0.78
Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo. Metabolism (1980) 0.78
Effects of prosomatostatin on growth hormone and prolactin response to arginine in man. Comparison with somatostatin. Lancet (1981) 0.78
Effect of human pancreatic polypeptide and its C-terminal hexapeptide on pancreatic secretion in man and in the dog. Scand J Gastroenterol (1982) 0.78
Human pancreatic polypeptide inhibits insulin release in the rat. Biochem Biophys Res Commun (1981) 0.78
Immunocytochemical localization of CRF in the ovine hypothalamus. Peptides (1982) 0.77
Secretion of interleukin-1 beta and Escherichia coli galactokinase by Streptomyces lividans. J Bacteriol (1988) 0.77
Micelle-bound conformational preferences of a peptide derived from a murine major histocompatibility complex class I molecule. J Biol Chem (1993) 0.77
Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci (1997) 0.77
Use of the mouse vas deferens assay to evaluate the action of somatostatin peptides on gastric acid secretion. Digestion (1981) 0.76
Successful treatment of interferon-alpha-induced mood disorder with nortriptyline. Psychosomatics (1995) 0.76
Peptides corresponding to the N and C termini of IkappaB-alpha, -beta, and -epsilon as probes of the two catalytic subunits of IkappaB kinase, IKK-1 and IKK-2. J Biol Chem (1999) 0.76
Impairment of remote memory after closed head injury. J Neurol Neurosurg Psychiatry (1985) 0.76
Sensitive radioimmunoassay for somatostatin using N-[125I]-Tyr-somatostatin as labelled antigen. Clin Endocrinol (Oxf) (1979) 0.75
Neurochemical basis of interleukin 2-modified discrimination behaviour. Cytokine (1994) 0.75
Introduction to hippocampal spectroscopy. Neuroimaging Clin N Am (1997) 0.75
Quality of life and neurobehavioural functioning in patients with malignant gliomas. Baillieres Clin Neurol (1996) 0.75
Differentiation of somatostatin receptors involved in inhibition of gastric acid and growth hormone secretion with halogenated Trp8 analogues [proceedings]. J Physiol (1978) 0.75
Solid-phase synthesis of human pancreatic polypeptide. Int J Pept Protein Res (1980) 0.75
Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly. Res Commun Chem Pathol Pharmacol (1984) 0.75
A pseudopeptide incorporating the tetrahydrophthalazine nucleus, a constrained aza analog of phenylalanine. Int J Pept Protein Res (1996) 0.75
Suppression of somatostatin levels in the hepatic portal and systemic plasma of the rat by synthetic human pancreatic polypeptide. Biochem Biophys Res Commun (1979) 0.75
The opioid mechanism of interferon-alpha action. Anticancer Drugs (1994) 0.75
Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin. Res Commun Chem Pathol Pharmacol (1984) 0.75